Kenson Ventures

Turning Point Therapeutics is a clinical-stage biopharmaceutical company focused on designing and developing novel small molecule targeted oncology therapies. Its pipeline includes repotrectinib, TPX-0046, TPX-0022, and preclinical ALK inhibitor TPX-0131, targeting genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Advanced Cell Diagnostics, Inc. is a biotechnology company specializing in the development and commercialization of cell and tissue-based diagnostic tests for personalized medicine. Founded in 2007 and based in Hayward, California, the company utilizes its proprietary RNAscope technology, a multiplex fluorescent and chromogenic in situ hybridization platform, to detect and quantify RNA biomarkers at single molecule sensitivity. Its product offerings include RNAscope manual assays and reagent kits, automated tissue staining solutions, catalog probes, and software for quantitative analysis of RNA in situ hybridization samples. Advanced Cell Diagnostics also provides pharmaceutical assay services to aid in understanding disease mechanisms and support preclinical and clinical research, including companion diagnostic assay development. The company serves a global market through a network of distributors in various countries and has a direct online presence.

GENEWIZ is a global genomics service company offering DNA sequencing, gene synthesis, molecular biology, next-generation sequencing, bioinformatics, and GLP regulatory services. Established in 1999, it serves pharmaceutical, biotechnology, academic, agricultural, government, and clinical institutions worldwide.

Diagnostic Hybrids, Inc. specializes in the development, manufacture, and marketing of cellular and molecular diagnostic kits aimed at detecting respiratory diseases, herpes infections, and other disease markers. The company's notable product, the D3 FastPoint L-DFA influenza A/influenza B virus identification kit, facilitates rapid identification of influenza viruses from patient specimens in under 30 minutes. In addition, Diagnostic Hybrids creates genetically engineered cell-based detection products tailored for the pharmaceutical and biotechnology sectors, particularly focusing on pharmacology assays and evaluating drug clearance as well as anti-viral intervention effectiveness. The company offers a diverse range of tools for specimen collection and transport, virus detection, and multi-virus cell culture amplification. Its product line includes tests for respiratory pathogens, herpes family viruses, and C. difficile toxins, among others. Furthermore, Diagnostic Hybrids provides in vitro toxicology and metabolism products and supports educational initiatives on various viral diseases through speaker programs and online resources. Founded in 1983, the company is headquartered in Athens, Ohio.

BioForm Medical, Inc. is a medical aesthetics company dedicated to developing and commercializing products that enhance patients' appearances. Its primary offering is RADIESSE, an injectable dermal filler that provides aesthetic improvements. In addition to RADIESSE, the company produces RADIESSE Voice and RADIESSE Voice Gel, which are used to address vocal fold insufficiency, and Coaptite, an injectable implant that acts as a bulking agent for treating stress urinary incontinence. BioForm Medical also provides Aethoxysklerol, an injectable sclerosing agent for varicose veins, and BioGlue, a surgical adhesive for facial aesthetic applications. The company's products are marketed through sales representatives and third-party distributors to dermatologists, plastic surgeons, and other physicians performing cosmetic procedures, both domestically and internationally.

System Biosciences develops and provides innovative tools for molecular and cell biology research. It offers a range of products including cloning vectors, siRNA libraries, stem cell research tools, microRNA tools, transcriptome RNA amplification kits, interferon response detection kits, and molecular tools. The company focuses on delivering the latest methodologies to market and maintains high product quality through in-house manufacturing. Its products are sold globally through distributors and online.

SABiosciences Corporation, established in 1998, is a privately held biotechnology company that focuses on advancing biological research in the post-genomic era. The company develops and commercializes a portfolio of real-time PCR-based assay panels that are designed to target specific diseases and biological pathways. By integrating hypothesis-driven and discovery-based research methodologies, SABiosciences aims to provide researchers with innovative tools that enhance the efficiency and effectiveness of their studies.

Epitomics is a biotechnology company based in Burlingame, California, with subsidiaries in Hong Kong and Hangzhou, China. It specializes in developing advanced monoclonal antibody technology for research and diagnostic purposes. Epitomics' proprietary RabMAb® technology enables the production of high-affinity, specific, and bioactive antibodies suitable for both in vitro and in vivo applications. The company's offerings include humanized rabbit monoclonal antibodies for potential therapeutic use.

Panomics, founded in 2000 by Yuling Luo and Jason Li, is a California-based company specializing in Parallel Quantitative Biology (PQB) solutions. The company offers a comprehensive suite of assay products designed for low to mid-plex genetic, protein, and cellular analysis applications. Panomics emphasizes the importance of contextual and systems-level measurements to enhance the understanding of genes, proteins, and their cellular functions. Its innovative approach serves a global market, providing essential tools for researchers and scientists in the fields of biology and biomedicine.